Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab

Table 2 Characteristics of ANCA-associated vasculitis patients who received rituximab for remission maintenance

Study place	N	Age	Men	PR3-ANCA	CYC	CYC	RTX	Kidney	Lung	Orb-Subg	BVAS	Time to RTX	FU mo	IgG before	IgG after	SI	HypoG	Ref
Study place	N	y	%	%	%	g	g	%	%	%		mo		g/L	g/l	%	%	Ref
Nottingham, UK	11	41	64	100	100	NR	8	55	46	NR	14	72	32	NR	NR	NR	9	25
Paris 2011, France	28	51	60	68	100	48	NR	32	64	14	15	84	38	7.8	7.0	11	11	26
Rochester, US	53	46	47	98	100	NR	NR	42	49	NR	5	120	53	8.4	5.7	NR	NR	28
Freiburg, Germany	37	62	57	81	92	12	NR	60	81	NR	13	99	30	9.9	NR	16	27	24
Boston, US	172	60	45	43	NR	NR	NR	62	44	NR	2	NR	25	NR	NR	15	10	29
Paris 2014, France	66	50	49	80	89	29	4.6	21	47	14	10	67	34	8.3	7.5	14	2	30
Uppsala, Sweden	12	NR	42	100	100	61	NR	50	100	42	9	35	79	8.5	6.8	33	NR	31
MC, France	80	53	NR	84	98	13	NR	55	71	10	7	54	18	NR	NR	15	NR	32
Mainritsan, France	57	54	65	77	100	7.3	2.5	70	58	NR	NR	3	28	6.1	6.9	19	NR	5
Cambridge, UK	69	52	41	74	91	13.5	6	12	29	12	NR	60	59	9.3	8.0	29	41	7
Tromsø, Norway	29	50	52	86	97	17	9	59	66	62	10	57	49	7.7	4.9	24	45	8

BVAS Birmingham Vasculitis Activity Score, CYC cyclophosphamide, FU follow-up during maintenance remission with rituximab, HypoG rate of hypogammaglobulinemia, MC multicentric study, N number of patients, NR not reported, Orb-Subg frequency of orbital-subglottic involvement, RTX rituximab, Ref reference, SI rate of severe infection

ISSN: 1471-2474